Oncologist : Impact Factor & More
eISSN: 1549-490XpISSN: 1083-7159
Open AccessShare this on:
Key Metrics
CiteScore 
8.5
Impact Factor
5 - 10
SNIP
1.61
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Oncologist Journal Specifications
| Overview | |
| Publisher | OXFORD UNIV PRESS |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 3494 |
| Publication Time | 19 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Society for Translational Oncology |
| Frequency | Monthly |
| Publication Start Year | 1996 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Oncologist ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Oncologist
Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.
- 30 Jun 2026
- The oncologist
Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.
- 29 Jun 2026
- The oncologist
Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.
- 29 Jun 2026
- The oncologist
Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.
- 29 Jun 2026
- The oncologist
Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.
- 29 Jun 2026
- The oncologist
Patient, Care Partner, and Oncologist Perspectives on Clinically Important Survival Thresholds After Considering Time Toxicity in Advanced Cancer.
- 27 Jun 2026
- The oncologist
Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.
- 30 Jun 2026
- The oncologist
Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.
- 29 Jun 2026
- The oncologist
Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.
- 29 Jun 2026
- The oncologist
Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.
- 29 Jun 2026
- The oncologist
Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.
- 29 Jun 2026
- The oncologist
Patient, Care Partner, and Oncologist Perspectives on Clinically Important Survival Thresholds After Considering Time Toxicity in Advanced Cancer.
- 27 Jun 2026
- The oncologist
FAQs on Oncologist
How long has Oncologist been actively publishing? 
What is the publishing frequency of Oncologist?
How many articles did Oncologist publish last year?
What is the eISSN & pISSN for Oncologist?
What is Citescore for Oncologist?
What is SNIP score for Oncologist?
Who is the publisher of Oncologist?
